Relay Therapeutics, Inc. (RLAY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on May 20, 2026. The filing discloses the entry into a Material Definitive Agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 22,916,667 shares of Common Stock initially offered.
- Offer Price: $12.00 per share.
- Over-Allotment Option: Underwriters exercised their option in full on May 21, 2026, to purchase an additional 3,437,500 shares.
- Total Shares Issued: 26,354,167 shares (initial offering plus full over-allotment).
- Estimated Net Proceeds: Approximately $296.8 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Expected Closing Date: May 22, 2026.
- Underwriters: Jefferies LLC and TD Securities (USA) LLC, as representatives.
Material Changes
The filing represents a significant capital raise event. The full exercise of the over-allotment option increases the total capital raised compared to the initial offering size. This transaction is expected to materially improve the Company's liquidity position upon closing.
Outlook, Risks, and Management Commentary
The Company states that the offering was made pursuant to an effective shelf registration statement on Form S-3ASR. The filing includes standard forward-looking statements regarding the anticipated closing of the offering. Management notes that actual results may differ due to market conditions and other uncertainties. Specific risks are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The filing does not provide specific operational guidance or updates on clinical trial progress beyond the context of the capital raise.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after all expenses.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.
- Assess the impact of the share dilution on existing shareholders given the issuance of 26,354,167 new shares.
- Consult the referenced Form 10-K (2025) and Form 10-Q (Q1 2026) for updated risk factors and cash burn rates.
- Confirm the use of proceeds as disclosed in the final prospectus supplement.